IBI 334
Alternative Names: IBI-334Latest Information Update: 19 Jun 2024
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical trial in Solid tumours was presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 03 Nov 2023 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (Parenteral) (NCT05774873)
- 28 Mar 2023 Preclinical trials in Solid tumours in China (unspecified route) (Innovent Biologics pipeline, March 2023)